A Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy

NCT03454620 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

53

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Colorectal Cancer
Solid Tumor

Interventions

DRUG: irinotecan
DRUG: FOLFIRI

Sponsor

Green Cross Corporation